Preparing for CAR-T Cell Therapy: The Weeks Before Infusion

Most descriptions of CAR-T cell therapy focus on the infusion — the moment the engineered cells go back in. For patients, though, the harder part is often what comes before it: several weeks of waiting while the cells are made, with the disease still present and two preparatory treatments to get through.

Knowing what happens during that window makes it easier to plan around, and easier to recognise what is normal.

This article walks through the preparation period, from the day cells are collected to the day they are returned.

In this article

• Why there is a waiting period at all


• Cell collection: what apheresis involves


• Bridging therapy


• Lymphodepletion


• Practical preparation


• Frequently asked questions


• Discussing your own timeline

Why there is a waiting period at all

CAR-T cell therapy is not a drug taken off a shelf. Each dose is manufactured from one patient's own cells, for that patient alone.

After collection, the cells travel to a laboratory, where a new receptor is introduced and the modified population is grown into the hundreds of millions. Quality testing follows. The whole sequence typically takes several weeks.

Nothing can compress this. What can be managed is the disease during that time, which is where bridging therapy comes in.

Cell collection: what apheresis involves

The process begins with leukapheresis. Blood is drawn through a line, passed through a machine that separates out white blood cells, and returned to the body. Only the cells needed are kept.

It takes a few hours and is done while awake. There is no surgery and usually no overnight stay. Some patients feel tingling around the mouth or hands from the anticoagulant used in the circuit — this is common, expected, and corrected during the session.

Before this step, tests confirm that the cancer carries the target marker and that organ function is adequate. The full sequence is described on our CAR-T cell therapy page.

Bridging therapy

Cancer does not pause while cells are being manufactured. Bridging therapy is treatment given during this window to keep the disease under control.

It is deliberately modest. The aim is not to cure or even to achieve a major response — it is to hold the situation steady, without damaging the patient's condition before the main treatment arrives. Depending on the case it may be a low-dose chemotherapy regimen, targeted treatment, or radiotherapy to a specific site.

Not every patient needs it. Where the disease is slow-moving, the manufacturing weeks may pass without any intervening treatment.

Lymphodepletion

A few days before the infusion comes lymphodepletion — a short course of low-dose chemotherapy, usually over about three days.

Its purpose is often misunderstood. It is not aimed at the cancer. It temporarily reduces the patient's existing lymphocytes to create space, so the returning engineered cells can expand rather than compete for room and resources. Without it, the infused cells expand far less effectively.

Because it lowers blood counts, the days that follow bring increased infection risk and fatigue. This is expected and monitored.

Then, typically two to fourteen days later depending on protocol, the cells are infused.

Practical preparation

Beyond the medical steps, several practical things are worth arranging early.

Staying near the treating centre. Patients are usually asked to remain close by for several weeks after infusion, since the strongest reactions occur early.

A caregiver. Most centres require someone to stay with the patient during that period and to recognise warning signs such as fever or confusion.

Dental and infection checks. Existing infections are treated beforehand, since immunity will be reduced.

Time away from work. The full sequence, from collection through recovery, spans a number of weeks.

Questions written down. The pace picks up once manufacturing finishes; it is easier to raise concerns while waiting than in the middle of treatment.

Discussing your own timeline

Every timeline differs, shaped by the disease, the centre and how manufacturing proceeds.

If you would like your case reviewed and the schedule explained for your situation, contact our team.

This article is general information about preparing for CAR-T cell therapy. It is not medical advice and does not replace consultation with a qualified physician.